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Summary
DNA repair deficiencies are common among cancer cells and represent a potential vulnerability 
that might be exploited by targeting compensatory repair pathways. However, the identification of 
synthetically lethal combinations of DNA repair defects, while of significant clinical relevance, 
has been somewhat anecdotal. While numerous models have been proposed to explain synergy 
among DNA repair mutations, we have only a limited understanding of why a given mutation 
should render cells sensitive another. In this issue of Cancer Discovery, Reinhardt and colleagues 
define a general connection between mutations in genes involved in homologous recombination 
and sensitivity to inhibitors of non-homologous end joining. In doing so, they provide a 
mechanism to demarcate a set of seemingly diverse tumors that may be highly responsive to 
established DNA repair-targeted therapeutics.
A central objective of cancer genome sequencing efforts has been to pair specific genomic 
alterations with actionable therapeutic strategies. This objective stems from the idea that 
mutations that promote cancer development also represent vulnerabilities that can be 
exploited given the appropriate therapy. Noteworthy examples of this phenomenon exist in 
the realm of oncogene addiction, in which the expression of mutant driver oncogenes 
renders tumor cells exquisitely sensitive to targeted oncogene inhibition. This approach has 
led to dramatic, albeit sometimes transient, responses in numerous treatment-refractory 
tumors. However, this type of mutation-targeted therapy represents the exception as opposed 
to the rule for the treatment of most cancers.
Perhaps the most conceptually advanced paradigms for pairing tumor mutations with 
targeted therapies stem from studies examining alterations resulting in genomic instability or 
abrogation of the DNA damage response (1). These studies have yielded two basic strategies 
to target tumor cell vulnerabilities. The first strategy is to disable a cancer cell’s ability to 
undergo cell cycle arrest in response to DNA-damaging chemotherapy. Cells with persistent 
damage undergo a process termed “mitotic catastrophe” if unable to undergo G1/S or G2/M 
cell cycle arrest. Given that tumor cells frequently carry mutations that abrogate cell cycle 
checkpoints, targeted therapies that block remaining cell cycle arrest pathways would be 
expected to have pronounced tumor-specific effects. This process has been described in 
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studies examining combined p53 and ATM (2), p53 and MK2 (3) and p53 and Chk1 
deficiency (4, 5). In each case, p53-deficiency disables the G1/S checkpoint, while therapies 
targeting mediators of the G2/M checkpoint promote mitotic catastrophe in the presence of 
genotoxic damage.
A second, analogous, approach is to profoundly disrupt a cancer cell’s ability to repair DNA 
damage. Genomic instability is a common feature of tumor cells and is thought to represent 
a basic mechanism to acquire the multiple genetic alterations required during the neoplastic 
process. Cells showing genomic instability retain some capacity to repair DNA damage, as a 
complete absence of repair mechanisms would lead to a dramatic loss in genomic integrity – 
particularly in the presence of DNA-damaging therapy. Thus, tumor cells with partial 
defects in DNA repair are potentially highly sensitized to therapeutics targeting residual 
DNA repair capabilities. The most dramatic example of this process involves the treatment 
of breast and ovarian cancers with Brca1/2 deficiency (6, 7). Inactivation of Brca1/2 results 
in severe defects in the ability of cells to repair DNA damage by homologous recombination 
(HR). Small molecule inhibition of Poly ADP Ribose Polymerase (PARP) proteins, involved 
in a diverse set of cellular processes including DNA repair, specifically promotes the death 
of Brca1/2 deficient cells. This process is thought to arise through the disruption of parallel 
DNA repair pathways and is further exacerbated in the presence of DNA damage. An 
additional example of this kind of combined DNA repair defect occurs when targeting both 
ATM and DNA-PK (2). However, despite an increasing number of “target pairs” that show 
synthetic lethality, we still lack a systematic and coherent understanding of which specific 
DNA repair defects render tumor cells particularly sensitive to targeting specific DNA repair 
proteins. In this issue of Cancer Discovery, Reinhardt and colleagues provide needed 
resolution to this issue (8). By probing diverse cancer cells lines for sensitivity to a DNA-PK 
inhibitor, they cement a connection between defects in homologous recombination (HR) and 
drugs that target non-homologous end joining (NHEJ). In doing so, they provide a clear 
rationale for the treatment of a diverse set of tumors bearing similar DNA repair 
deficiencies.
As a precursor to this study, Reinhardt and colleagues identified ATM deficiency as a tumor 
alteration that sensitized tumor cells to DNA-PK chemical or genetic targeting (9). While it 
is clear that DNA-PK plays a central role in double-strand break repair by homologous 
recombination, ATM is putatively involved in a diverse set of cellular processes including 
DNA damage signaling and DNA repair. Thus, the basic mechanism of synergy for these 
two alterations remained somewhat speculative. In the extant study, they used a set of 94 
well-characterized cell lines to explore sensitivity to DNA-PK inhibition in a more unbiased 
manner. The mutational spectra in each cell line allowed them to stratify relative sensitivity 
to DNA-PK inhibition based on defined genetic alterations. Strikingly, alterations that 
correlated with the greatest sensitivity to DNA-PK inhibition represented mutations in genes 
implicated in HR. These included mutations in BRCA2, RAD50, CHEK2, PAXIP and 
FANCD2, as well as, at lower frequency, mutations in BRCA1 and ATM. The alterations 
most frequently associated with DNA-PK sensitivity were inactivating mutations in MSH3 – 
a gene with established roles in mismatch repair (MMR) and HR. MSH3 mutations are 
found in as many as 7% of all colon cancers (10), making this connection between MSH3 
mutation and sensitivity to a targeted therapeutic a finding of considerable clinical 
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relevance. Indeed, a great strength of their approach is that by screening cells lines for 
sensitivity to a targeted therapeutic, the identification of robust sensitizing mutations leads 
immediately to a actionable pairing of an existing drug with a cancer-relevant lesion.
While the DNA-PK/MSH3 interdependency represents a clinically important concept, 
perhaps even more relevant is the global connection between defects in HR and sensitivity 
to inhibition of NHEJ. To more extensively explore this phenomenon, this authors examined 
whether their sensitive cell lines actually exhibited HR defects. Using the appearance of 
Rad51 foci as a marker for HR following DNA damage, they showed an absence of these 
foci in cells sensitive to DNA-PK inhibition. Moreover HR-defective cells treated with a 
DNA-PK inhibitor showed a persistence of DNA breaks following genotoxic damage that is 
characteristic of a global inability to repair DNA damage. Finally, to establish the reciprocal 
nature of this HR/NHEJ dependency, they examined whether additional NHEJ defects 
render cells sensitive to MSH3 deficiency. Here, they used RNAi to silence Ku70 and Ku80, 
two proteins essential for NHEJ, in cancer cell lines with MSH3 mutations. Here, again, 
they observed synergy between defects in NHEJ and HR.
These data strongly suggest that one can move beyond anecdotal pairs of synthetically lethal 
drug/genotype combinations and begin to think about how a diversity of defects in the same 
pathway may yield common vulnerabilities. Thus, tumors might be binned into categories of 
repair defects rather than more complex mutational spectra. However, multiple significant 
challenges remain in moving this approach towards clinical implementation. First, our 
estimation of the relevance of a gene to a specific repair process does not necessarily 
correlate with the degree to which its inactivation might sensitize cells to a second repair 
defect. For example, in this study Brca1 and ATM mutations were only weakly correlated 
with sensitivity to DNA-PK inhibition. Moreover, some, but not other, ATM mutations 
sensitized cells to NHEJ deficiency. Thus, we need to more completely understand the 
specific nature of the DNA repair defect to predict the effect of a given mutation has on a 
repair process. Second, tumors bear a diverse set of alterations, and it may be difficult to 
infer the effect of any single alteration on global repair processes. In this study, the authors 
describe a cell line that was heterozygous for a BRCA1 mutation but was, unexpectedly, 
sensitive to DNA-PK inhibition. Further analysis of this cell line revealed a MSH3 mutation 
that likely underlies drug sensitivity. Thus, a clear understanding of how mutations act in 
concert to affect repair processes may be necessary to predict the response to drugs targeting 
parallel repair pathways.
One solution to these challenges would be to attempt to stratify tumors based on certain 
functional processes as opposed to specific mutations. Given the idea that we might target 
global repair defects like “HR-deficiency”, it would be of tremendous value to develop 
assays that could interrogate ongoing repair processes in human cancers. Most pathological 
analysis of tumors relies on examining a static entity, yet the identification of specific DNA 
repair defects requires the observation of DNA integrity over time. In some cases, it requires 
the introduction of an exogenous substrate into tumor cells to examine a repair process. 
While such approaches are certainly challenging, they would allow one to define a tumor in 
terms of an ongoing repair defect as opposed to intuiting a repair defect based on a set of 
characteristic mutations.
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Figure 1. 
Mutually informative processes govern the use DNA repair inhibitors in repair-deficient cell 
lines. A) Screening for cell lines sensitive to NHEJ inhibition identifies mutations that 
define a set of DNA-PK-dependent tumors. B) Sensitizing mutations implicate HR-
deficiency as the major defect underlying DNA-PK dependence. This suggests that other 
HR-mutations not found in this study may similarly sensitize tumors to DNA-PK inhibition. 
C) Tumor cells can similarly be defined as sensitive to a DNA-PK inhibitor or having 
defects in HR. This suggests that tumor cells with an HR defect – even in the absence of an 
HR-related mutation – would be sensitive to DNA-PK inhibition.
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